Stephens Consulting’s Genmab GMAB Stock Holding History

Stephens Consulting’s Portfolio GMAB Stock Details GMAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-79	Closed	-$1.63K	–	704
2025 Q2	$1.63K	Buy	+79	New	+$1.62K	﹤0.01%	540

Other funds holding GMAB

OAG

Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Harding Loevner Bridgewater, New Jersey $9.72B AUM 22.38% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Stephens Consulting's GMAB Position: Q3 2025 in Review

Stephens Consulting sold out of Genmab (GMAB) in Q3 2025, closing a stake of 79 shares — an estimated $1.63K sold.

Stephens Consulting first reported a position in GMAB in Q2 2025 and held it in 1 quarter. The position peaked at $1.63K in Q2 2025. 252 funds tracked by Wall St. Rank hold GMAB as of Q3 2025.

Stephens Consulting reported no remaining Genmab position as of Q3 2025 after selling out during the quarter.
Stephens Consulting sold 79 Genmab shares in Q3 2025, an estimated $1.63K.
Stephens Consulting first reported a position in Genmab in Q2 2025 and held it in 1 quarter.
Stephens Consulting's Genmab position peaked at $1.63K in Q2 2025.
252 funds tracked by Wall St. Rank held Genmab as of Q3 2025.

Based on Stephens Consulting's 13F filing for Q3 2025, filed 15 Oct 2025.